Reproductive Outcome Registration in Phase 3 Weight‐Management Pharmacotherapy Trials: A Cross‐Sectional Meta‐Research Study
Rana Mondal, Mouli NandiABSTRACT
Aims
To quantify registered reproductive outcome measures in women and men in adult Phase 3 weight‐management pharmacotherapy trials and compare them with registered body‐composition measures.
Materials and Methods
Cross‐sectional meta‐research study of
Results
Of 230 trials (91 development programmes; 3711 registered outcome measures), two registered any reproductive outcome measure (0.87%, 95% CI: 0.11–3.11), both in polycystic ovary syndrome populations with non‐industry sponsors; none of 227 trials without a reproductive indication did. No trial enrolling men registered a named male gonadal‐endocrine or semen measure (0/228, 95% CI: 0.00–1.60). Among trials of glucagon‐like peptide‐1‐based agents it was 2/152 (1.32%). Body composition was registered in 33 trials, 31 without any reproductive measure and none the reverse; at programme level, 22 versus none. Admitting trials with minimum age below 18 years gave 7/254 (2.76%), including two industry trials registering gonadal hormones in adolescent safety panels.
Conclusions
Qualifying reproductive outcomes were rarely registered in adult Phase 3 weight‐management pharmacotherapy trials on